EGFR and neoplasm: In this study, tissue EGFR results would have yielded additional findings in 5.56% (3/54) of cases, for which plasma NGS did not find the EGFR mutation present in the tumor, supporting the complementary plasma testing would be the most informative approach for the NSCLC patient population.